Mabgalaxy completes ~￥100M angel round financing to advance innovative antibody drug R&D and pipeline development

On March 23, 2026, Mabgalaxy, a biopharmaceutical company focused on the research and development of next-generation antibody therapeutics for inflammatory and autoimmune diseases, announced the completion of its nearly RMB 100 million angel round financing. This round was led by Lapam Capital, with participation from Nest.Bio Ventures, Yijing Capital, and Yuanbio Venture Capital. Yuan Yi Capital served as the exclusive financial advisor.

Mabgalaxy integrates its antibody discovery platform with the MabAI intelligent algorithm to continuously enhance early-stage R&D efficiency and candidate molecule quality. The proceeds from this round will primarily be used to advance core pipeline research, upgrade technological platforms, expand the team, and accelerate preclinical studies and subsequent development of multiple innovative antibody programs.

Mabgalaxy was founded by Dr. Liang Qi, a seasoned antibody expert of Chinese origin. The core team possesses deep expertise in antibody drug development, industrial translation, and international collaboration, with a track record of successfully founding a biotech company that was subsequently acquired by a globally renowned multinational pharmaceutical company for over USD 1 billion. This rare combination of global R&D and transaction execution capabilities provides a robust foundation for Mabgalaxy's future product development, business development, and internationalization efforts.

Mabgalaxy is dedicated to the inflammatory and autoimmune disease space, striving to develop innovative antibody therapeutics with differentiated competitive advantages. The company has established systematic R&D capabilities encompassing target discovery, antibody design, molecular optimization, and preclinical evaluation, and is advancing an innovative pipeline aimed at the global market.

Currently, Mabgalaxy has built a portfolio of innovative antibody programs with differentiated potential in inflammation and autoimmune diseases, focusing on early-stage projects with global development value. These R&D efforts address significant unmet clinical needs, cover multiple types of inflammatory and autoimmune diseases, and hold potential for further expansion into additional indications.

In its R&D strategy, Mabgalaxy combines antibody engineering expertise with computational methods to continuously optimize key processes such as target screening, antibody sequence design, developability assessment, and candidate molecule selection. This approach aims to improve R&D efficiency and enhance the translational potential of its candidate molecules.